{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:33:13Z","timestamp":1780579993009,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11606-019-04858-2","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T21:18:32Z","timestamp":1551993512000},"page":"862-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial"],"prefix":"10.1007","volume":"34","author":[{"given":"Robert M.","family":"Anthenelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal L.","family":"Benowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"St. Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Krishen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Eden","family":"Evins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"issue":"10037","key":"4858_CR1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","volume":"387","author":"RM Anthenelli","year":"2016","unstructured":"Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507\u201320.","journal-title":"Lancet."},{"issue":"6","key":"4858_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2165\/00002018-199920060-00007","volume":"20","author":"SG Gourlay","year":"1999","unstructured":"Gourlay SG, Forbes A, Marriner T, McNeil JJ. Predictors and timing of adverse experiences during transdermal nicotine therapy. Drug Saf. 1999;20(6):545\u201355.","journal-title":"Drug Saf."},{"issue":"3","key":"4858_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/14622200801901971","volume":"10","author":"AM Leventhal","year":"2008","unstructured":"Leventhal AM, Ramsey SE, Brown RA, LaChance HR, Kahler CW. Dimensions of depressive symptoms and smoking cessation. Nicotine Tob Res. 2008;10(3):507\u201317.","journal-title":"Nicotine Tob Res."},{"issue":"1","key":"4858_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/10550887.2012.759870","volume":"32","author":"RA Schnoll","year":"2013","unstructured":"Schnoll RA, Leone FT, Hitsman B. Symptoms of depression and smoking behaviors following treatment with transdermal nicotine patch. J Addict Dis. 2013;32(1):46\u201352.","journal-title":"J Addict Dis."},{"issue":"3","key":"4858_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.pbb.2007.12.020","volume":"89","author":"HE Morrell","year":"2008","unstructured":"Morrell HE, Cohen LM, al'Absi M. Physiological and psychological symptoms and predictors in early nicotine withdrawal. Pharmacol Biochem Behav. 2008;89(3):272\u20138.","journal-title":"Pharmacol Biochem Behav."},{"issue":"7","key":"4858_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/0269881115575536","volume":"29","author":"SG Farris","year":"2015","unstructured":"Farris SG, Zvolensky MJ, Otto MW, Leyro TM. The role of distress intolerance for panic and nicotine withdrawal symptoms during a biological challenge. J Psychopharmacol. 2015;29(7):783\u201391.","journal-title":"J Psychopharmacol."},{"issue":"6","key":"4858_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00038-016-0818-8","volume":"61","author":"Z Ben Taleb","year":"2016","unstructured":"Ben Taleb Z, Ward KD, Asfar T, Jaber R, Auf R, Maziak W. Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting. Int J Public Health. 2016;61(6):701\u20138.","journal-title":"Int J Public Health."},{"key":"4858_CR8","doi-asserted-by":"crossref","unstructured":"World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available at: \n                    https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/\n                    \n                  . Accessed Dec 14 2018.","DOI":"10.1515\/9783110208856.233"},{"key":"4858_CR9","unstructured":"International Conference on Harmonisation. Guideline For Good Clinical Practice E6(R2). Available at: \n                    https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf\n                    \n                  . Accessed Dec 14 2018."},{"key":"4858_CR10","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). In: Rush Jr AJ, First MB, Blacker D, editors. Handbook of Psychiatric Measures. 2nd ed. Arlington, VA, US: American Psychiatric Publishing Inc.; 2008:40\u20133."},{"key":"4858_CR11","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revison. Available at: \n                    https:\/\/dsm.psychiatryonline.org\/doi\/abs\/10.1176\/appi.books.9780890420249.dsm-iv-tr\n                    \n                  . Accessed Dec 14 2018."},{"key":"4858_CR12","volume-title":"Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II)","author":"MB First","year":"1997","unstructured":"First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, D.C.: American Psychiatric Press, Inc.; 1997."},{"key":"4858_CR13","volume-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I\/P)","author":"MB First","year":"2002","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I\/P). New York: Biometrics Research, New York State Psychiatric Institute; November 2002."},{"issue":"1","key":"4858_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ntr\/ntr137","volume":"14","author":"K Fagerstr\u00f6m","year":"2012","unstructured":"Fagerstr\u00f6m K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res. 2012;14(1):75\u20138.","journal-title":"Nicotine Tob Res."},{"issue":"3","key":"4858_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1037\/0022-3514.63.3.452","volume":"63","author":"AH Buss","year":"1992","unstructured":"Buss AH, Perry M. The aggression questionnaire. J Pers Soc Psychol. 1992;63(3):452\u20139.","journal-title":"J Pers Soc Psychol."},{"issue":"12","key":"4858_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"4858_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand."},{"issue":"6","key":"4858_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7326\/0003-4819-159-6-201309170-00005","volume":"159","author":"RM Anthenelli","year":"2013","unstructured":"Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013;159(6):390\u2013400.","journal-title":"Ann Intern Med."},{"key":"4858_CR19","volume":"11","author":"LF Stead","year":"2012","unstructured":"Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.","journal-title":"Cochrane Database Syst Rev."},{"key":"4858_CR20","volume":"1","author":"JR Hughes","year":"2014","unstructured":"Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;1:CD000031.","journal-title":"Cochrane Database Syst Rev."},{"key":"4858_CR21","volume":"5","author":"K Cahill","year":"2013","unstructured":"Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.","journal-title":"Cochrane Database Syst Rev."},{"key":"4858_CR22","volume":"5","author":"K Cahill","year":"2016","unstructured":"Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;5:CD006103.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"4858_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.drugalcdep.2008.06.003","volume":"98","author":"JR Hughes","year":"2008","unstructured":"Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend. 2008;98(3):169\u201378.","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"4858_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000876","volume":"2","author":"LS Covey","year":"2012","unstructured":"Covey LS, Berlin I, Hu MC, Hakes JK. Smoking and suicidal behaviours in a sample of US adults with low mood: a retrospective analysis of longitudinal data. BMJ Open. 2012;2(3):e000876.","journal-title":"BMJ Open."},{"issue":"12","key":"4858_CR25","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1017\/S0033291717000587","volume":"47","author":"AE Evins","year":"2017","unstructured":"Evins AE, Korhonen T, Kinnunen TH, Kaprio J. Prospective association between tobacco smoking and death by suicide: a competing risks hazard analysis in a large twin cohort with 35-year follow-up. Psychol Med. 2017;47(12):2143\u201354.","journal-title":"Psychol Med."},{"key":"4858_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpsychires.2016.09.018","volume":"84","author":"R Gaspersz","year":"2017","unstructured":"Gaspersz R, Lamers F, Kent JM, Beekman AT, Smit JH, van Hemert AM, et al. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment. J Psychiatr Res. 2017;84:41\u20138.","journal-title":"J Psychiatr Res."},{"issue":"4","key":"4858_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4088\/JCP.15m10370","volume":"78","author":"SA Shankman","year":"2017","unstructured":"Shankman SA, Gorka SM, Katz AC, Klein DN, Markowitz JC, Arnow BA, et al. Side effects to antidepressant treatment in patients with depression and comorbid panic disorder. J Clin Psychiatry. 2017;78(4):433\u201340.","journal-title":"J Clin Psychiatry."},{"key":"4858_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.yebeh.2015.03.005","volume":"46","author":"SK Kim","year":"2015","unstructured":"Kim SK, Park SP, Kwon OY. Impact of depression and anxiety on adverse event profiles in Korean people with epilepsy. Epilepsy Behav. 2015;46:185\u201391.","journal-title":"Epilepsy Behav."},{"issue":"3","key":"4858_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1212\/WNL.0b013e318207b073","volume":"76","author":"P Perucca","year":"2011","unstructured":"Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EK, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology. 2011;76(3):273\u20139.","journal-title":"Neurology."},{"key":"4858_CR30","doi-asserted-by":"crossref","unstructured":"Minami H, Frank BE, Bold KW, McCarthy DE. Ecological momentary analysis of the relations among stressful events, affective reactivity, and smoking among smokers with high vs. low depressive symptoms during a quit attempt. Addiction. 2017.","DOI":"10.1111\/add.13964"},{"issue":"2","key":"4858_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.psyneuen.2007.10.014","volume":"33","author":"RY Chong","year":"2008","unstructured":"Chong RY, Uhart M, McCaul ME, Johnson E, Wand GS. Whites have a more robust hypothalamic-pituitary-adrenal axis response to a psychological stressor than blacks. Psychoneuroendocrinology. 2008;33(2):246\u201354.","journal-title":"Psychoneuroendocrinology."},{"key":"4858_CR32","unstructured":"Shivani R, Goldsmith RJ, Anthenelli RM. Alcoholism and Psychiatric Disorders: Diagnostic Challenges. Available at:\n                           \n                    https:\/\/pubs.niaaa.nih.gov\/publications\/arh26-2\/90-98.htm\n                    \n                  . Accessed Dec 14 2018."},{"issue":"10","key":"4858_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.7326\/M14-0589","volume":"160","author":"ML LeFevre","year":"2014","unstructured":"LeFevre ML, Force USPST. Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(10):719\u201326.","journal-title":"Ann Intern Med."},{"issue":"4","key":"4858_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2015.18392","volume":"315","author":"AL Siu","year":"2016","unstructured":"Siu AL, Force USPST, Bibbins-Domingo K, Grossman DC, Baumann LC, Davidson KW, et al. Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(4):380\u20137.","journal-title":"JAMA."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-04858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-019-04858-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-04858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T01:08:51Z","timestamp":1583543331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-019-04858-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4858"],"URL":"https:\/\/doi.org\/10.1007\/s11606-019-04858-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see https:\/\/ for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the USA and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24\u00a0months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RMA reports his university receiving grants from Alkermes and Pfizer and providing consulting and\/or advisory board services to Arena Pharmaceuticals, Cerecor, Pfizer, and US WorldMeds. RMA\u2019s writing of this manuscript was supported, in part, by National Institute on Alcohol Abuse and Alcoholism Grant no. U01 AA013641, and National Institute on Drug Abuse (NIDA) Grant no. UO1 DA041731, and NIDA\/Veterans Affairs Cooperative Study no. 1033. NLB reports consulting and\/or advisory board services to GlaxoSmithKline, Pfizer, and Achieve Life Sciences and is a paid expert witness in litigation against tobacco companies. RW reports grants from Johnson & Johnson and Pfizer and personal fees for consulting and\/or advisory board services to GlaxoSmithKline, Johnson & Johnson, and Pfizer. RW\u2019s writing of this manuscript was supported, in part, by Cancer Research United Kingdom. AEE reports grants from Forum Pharmaceuticals and Pfizer and personal fees for advisory board services from Pfizer, Reckitt Benckiser, and Alkermes. AEE\u2019s writing of the manuscript was supported by a NIDA Career Award in Patient-Oriented Research, K24 DA030443. MG, TM, CR, DL, and LSA are employees and stockholders of Pfizer. AK is a PAREXEL employee working on behalf of GlaxoSmithKline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The opinions expressed in this article are those of the authors and do not necessarily reflect the views of their employers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}